On 28 January 2020,­ Race Oncology Limited announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director. Prof Andersson is an internationally acclaimed leader in the field of leukaemia and stem cell transplantation research at the MD Anderson Cancer Centre in Houston, Texas. Prof Andersson was previously engaged as a scientific and clinical consultant to the Company and was recently appointed Chair of RAC's Clinical Advisory Board. Prof Andersson will be focused on the clinical strategy of both the Company's planned Phase I/II paediatric AML and Phase II AML MRD trials. He will also advise on Race's other clinical trial programs in Adult AML, Breast Cancer and Ovarian Cancer. Prof Andersson's network and expertise will greatly assist in expediting Race's clinical trials, partnership initiatives and commercialisation activities.